Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
| ▸ | HPD | P32754 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449181 | 0.94 | PDE10A (0.47) | PDE10ASMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL449367 | 0.94 | SMN1; SMN2 (0.47) | SMN1; SMN2KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL451808 | 0.91 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL448566 | 0.90 | ALDH1A1 (0.56) | PDE10ASMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL452808 | 0.87 | SMN1; SMN2 (0.47) | PDE10ASMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL451852 | 0.86 | ALDH1A1 (0.45) | PDE10ASMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL448509 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL452955 | 0.85 | SMN1; SMN2 (0.43) | SMN1; SMN2KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL453876 | 0.84 | PDE10A (0.50) | PDE10ASMN1; SMN2CXCR3HPD | |
| SCHEMBL450570 | 0.83 | SMN1; SMN2 (0.43) | SMN1; SMN2KDM4EALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| EP-1521746-B1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | PDE10A 1893/4885SMN1; SMN2 4873/4885KDM4E 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.